Is Methylphenidate legal in New Zealand?

Also known as: ritalin

Legal status

Controlled, and named rather than inferred. Schedule 2 of the Misuse of Drugs Act 1975 names or describes methylphenidate, a piperidine stimulant used for attention deficit hyperactivity disorder, as a Class B controlled drug, and the entry reaches its named salt, preparation or mixture. New Zealand's list is closed for named substances, so a named entry settles the class without recourse to the section 2 controlled-drug-analogue limb that carries sixteen other rows in this table. Adderall has its own row here and resolves through the amphetamine entry at the same Class B, so the two common stimulant medicines for that condition share a class. This was read against the consolidation current at 20 September 2026; the 2026 Classification and Presumption of Supply Order was made but no commencement instrument was located by that horizon, so nothing it proposes is treated as law here.

Consequences if caught

Capital exposure: none. There is no capital sentence in New Zealand, and section 6 reserves life imprisonment for Class A. So for methylphenidate the section 6 dealing maximum is 14 years and the section 7 possession maximum is 3 months. Neither is mandatory, and the Schedule 5 quantity for this class shifts a case toward supply rather than fixing its outcome. Passing tablets to a classmate or a colleague is supply under section 6 and carries the same figure as any other dealing in this class.

If prescribed or medical

Not established for a traveller. This dossier carries no country-level rule for entering New Zealand with a prescribed medicine: it records that medicines status has to be checked alongside the analogue exclusions and the Psychoactive Substances Act 2013 route, and that a court-grade conclusion can turn on the medicine exclusions, but it states no declaration requirement, no permit, no quantity allowance and no carry limit at the border, and none was researched for this cell. What is established is the placement a traveller would be read against: methylphenidate is a Class B controlled drug under Schedule 2, with sections 6 and 7 supplying the offences. This is among the most commonly carried prescribed medicines in the whole table, so the absence of a stated border rule matters more here than almost anywhere else. Do not read that placement as a ruling on a lawfully prescribed and lawfully carried supply, which is a different question this cell does not answer. Settle the border question with the Ministry of Health, whose classification order implementation page this dossier cites, and with the New Zealand border authority, before travelling.

Documentation

Carry the Misuse of Drugs Act 1975 consolidation current at 20 September 2026, which is the official New Zealand Legislation text rather than a secondary summary. Read the Schedule 2 methylphenidate entry beside section 7, and keep the prescribing question separate from the class question. Carry the class and the ceiling as two separate readings, because Schedule 2 supplies the class for methylphenidate while sections 6 and 7 supply the maximum. Carry the classification chain this finding was read against as well: the 2022 and 2025 Classification and Presumption of Supply Orders with their commencement orders, the 2024 pseudoephedrine amendment, and the 2026 Order, which was made but is not treated as law in this dossier because its own section 2 leaves commencement to the Governor-General and no commencement instrument was located by the horizon. Carry the date as well, 20 September 2026, because in New Zealand a classification order can move a substance between classes without a word of the Act changing.

Drug laws and enforcement change and vary within a country. This is not legal advice. Always confirm with New Zealand’s embassy or official drug authority before traveling; penalties can be severe, including imprisonment.